[CAS NO. 303094-67-9] ZINC69391
PRODUCTS SPECIFICATIONS [303094-67-9]
DESCRIPTION [303094-67-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 309.29 |
| Molecular Formula | C14H14F3N5 |
| SMILES | N=C(NC1=CC=CC=C1C(F)(F)F)NC2=NC(C)=CC(C)=N2 |
Summary
ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis , and shows antiproliferative and antimetastatic effects [1] [2] [3] .
In Vitro
ZINC69391 inhibits growth of U937, HL-60, KG1A and Jurkat cells with IC
50
s ranging from 41 to 54 μM
[1]
.
ZINC69391 (50-100 μM; 24 hours) augments the enzymatic activity of caspase 3 in a concentration dependent manner
[1]
.
ZINC69391 (0-125 μM; 72h) reduces cell proliferation of human glioma cells
[2]
.
ZINC69391 (50-100 μM; 48 hours) triggers cell cycle arrest
[2]
.
ZINC69391 (50 μM; 24 hours) triggers apoptosis on human acute leukemic cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | U-87 MG, LN229 cells |
| Concentration: | 0-125μM |
| Incubation Time: | 72 hours |
| Result: | Reduced cell proliferation in a concentration-dependent manner. |
Cell Cycle Analysis [2]
| Cell Line: | LN229 cells |
| Concentration: | 50, 100 μM |
| Incubation Time: | 48 hours |
| Result: | Resulted in a significant increased percentage of cells in the sub-G0/G1 phase in a concentration dependent manner. |
Apoptosis Analysis [1]
| Cell Line: | HL-60, U937 and KG1A cell lines |
| Concentration: | 50 μM |
| Incubation Time: | 24 hours |
| Result: | Led to a significant increase in apoptotic cells. |
In Vivo
ZINC69391 (25 mg/kg; i.p; daily for 21 days) impairs metastatic lung colonization in a syngeneic animal model [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Specific pathogen-free female BALB/c inbred mice (bearing F3II cells) [3] |
| Dosage: | 25 mg/kg body weight |
| Administration: | I.p; daily for 21 days |
| Result: | Significantly reduced by about 60% the formation of total metastatic lung colonies. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 80.83 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2332 mL | 16.1661 mL | 32.3321 mL |
| 5 mM | 0.6466 mL | 3.2332 mL | 6.4664 mL |
| 10 mM | 0.3233 mL | 1.6166 mL | 3.2332 mL |
References
- [1] Cabrera M, et al. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017;8(58):98509‐98523. Published 2017 Oct 4.
- [2] Cardama GA, et al. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. Onco Targets Ther. 2014;7:2021‐2033. Published 2014 Oct 30.
- [3] Cardama GA, et al. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 2014;14(6):840‐851.